TELK Share Price

Open 5.10 Change Price %
High 5.50 1 Day 0.00 0.00
Low 5.10 1 Week 0.00 0.00
Close 5.50 1 Month 0.00 0.00
Volume 841 1 Year 0.00 0.00
52 Week High 121.94
52 Week Low 95.68
TELK Important Levels
Resistance 2 5.87
Resistance 1 5.72
Pivot 5.37
Support 1 5.28
Support 2 5.13
NASDAQ USA Most Active Stocks
DCTH 0.15 -11.76%
YHOO 52.58 0.00%
YHOO 52.58 0.00%
YHOO 52.58 0.00%
FNFG 10.18 -0.20%
DELL 13.86 0.22%
RFMD 16.59 -2.07%
QQQ 141.23 -0.07%
RIMM 13.03 0.39%
BBEP 0.12 0.00%
More..
NASDAQ USA Top Gainers Stocks
AMCF 0.03 50.00%
LOCM 0.09 50.00%
FALC 0.25 38.89%
VRTA 4.50 38.46%
ESMC 0.13 30.00%
BSDM 0.62 26.53%
SNTA 0.34 25.93%
STXS 0.68 25.93%
OTT 2.39 25.13%
ATRM 1.70 21.43%
More..
NASDAQ USA Top Losers Stocks
TXCC 0.01 -95.00%
HCIIP 10.10 -67.52%
CRMB 0.27 -57.81%
KIOR 0.03 -57.14%
PTSX 0.05 -50.00%
OSH 0.26 -49.02%
OSH 0.26 -49.02%
DVOX 0.05 -44.44%
PRXI 0.21 -43.24%
TRGT 0.96 -41.46%
More..

Telik, Inc. (NASDAQ: TELK)

TELK Technical Analysis 5
As on 9th Oct 2014 TELK Share Price closed @ 5.50 and we RECOMMEND Strong Buy for LONG-TERM with Stoploss of 1.34 & Strong Buy for SHORT-TERM with Stoploss of 1.32 we also expect STOCK to react on Following IMPORTANT LEVELS.
TELK Target for August
1st Target up-side N/A
2nd Target up-side N/A
3rd Target up-side N/A
1st Target down-side N/A
2nd Target down-side N/A
3rd Target down-side N/A
TELK Other Details
Segment EQ
Market Capital 3358708.75
Sector Healthcare
Industry Drugs - Generic
Offical website http://www.telik.com
TELK Address
TELK
2100 Geng Road
Suite 102
Palo Alto, CA 94303
United States
Phone: 650-845-7700
Fax: 650-845-7800
TELK Latest News
MabVax Therapeutics Board of Directors Authorizes the Company to Explore ...   PR Newswire (press release)   - 24th Jul 17
MabVax Therapeutics Announces $4.1 Million Public Offering   PR Newswire (press release)   - 16th May 17
MabVax Therapeutics to Present at the BIO CEO & Investor Conference   PR Newswire (press release)   - 10th Feb 17
MabVax Therapeutics: Opportunity In Unmet Cancer Need   Seeking Alpha   - 16th Nov 16
MabVax Therapeutics to Hold Conference Call to Provide Corporate Update On ...   PR Newswire (press release)   - 15th Nov 16
MabVax Therapeutics to Present at the 18th Annual Rodman & Renshaw Global ...   PR Newswire (press release)   - 31st Aug 16
MabVax Therapeutics Announces Uplisting to The Nasdaq Capital Market and $8 ...   PR Newswire (press release)   - 17th Aug 16
MabVax Therapeutics Holdings Hires Paul Resnick, MD as Chief Business Officer   PR Newswire (press release)   - 15th Apr 16
MabVax Therapeutics - A Bargain For Dr. Frost But Is It A Smart Buy For You?   Seeking Alpha   - 14th Apr 15
MabVax Therapeutics Holdings Inc.   Wall Street Journal   - 12th Oct 14
Interactive Technical Analysis Chart Telik, Inc. ( TELK NASDAQ USA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Telik, Inc.
TELK Business Profile
Telik, Inc. (Telik) is a clinical-stage drug development company focused on discovering and developing small molecule drugs to treat cancer. The Company discovers its product candidates using the Company�s drug discovery technology, Target-Related Affinity Profiling (TRAP). TELINTRA, its principal drug product candidate in clinical development, is a small molecule glutathione analog inhibitor of the enzyme glutathione S-transferase P1-1 (GST P1-1). TELCYTA, its other product candidate, is a small molecule cancer drug product candidate designed to be activated in cancer cells. In June 2011, the Company initiated a Phase II clinical trial to evaluate TELINTRA tablets. In October 2011, the Company initiated an additional Phase IIb clinical trial to evaluate TELINTRA tablets. As of December 31, 2011, Telik had an on-going investigator-led study at a single site of TELCYTA in patients with refractory or relapsed mantle cell lymphoma, diffuse B cell lymphom and multiple myeloma.